1	
2	Health Technology Assessment (HTA) readiness in Uganda: Stakeholder's perceptions on
3	the potential application of HTA to support National Universal Health Coverage efforts
4	^Ω Chrispus Mayora ¹ , ^Ω Joseph Kazibwe ² , Richard Ssempala ³ , Brenda Nakimuli ¹ , Aloysius
5	Ssenyonjo ¹ , Elizabeth Ekirapa ¹ , Sarah Byakika ⁴ , Tom Aliti ⁴ , Timothy Musila ⁴ , Mohamed Gad ² ,
6	Anna Vassall ² , Francis Ruiz ² , Freddie Ssengooba ¹
7	
8	1. Department of Health Policy and Planning, Makerere University School of Public Health,
9	Uganda
10	2. Department of Global Health, London School of Hygiene and Tropical Medicine, United
11	Kingdom
12	3. Department of Economic Theory and Analysis, Makerere University School of
13	Economics, Uganda
14	4. Department of Planning, Financing and Policy, Ministry of Health, Uganda
15	Ω - Joint first authors
16	
17	
18	Corresponding Author
19	Joseph Kazibwe
20	Department of Global Health and Development
21	London School of Hygiene and Tropical Medicine
22	United Kingdom
23	Joseph.kazibwe@lshtm.ac.uk

24	
25	
26	Abstract
27	Introduction
28	Health technology assessment (HTA) is an area that remains less implemented in low- and lower
29	middle-income countries. The aim of the study is to understand the perceptions of stakeholders
30	in Uganda towards HTA and its role in decision making, in order to inform its potential
31	implementation in the country.
32	
33	Methods
34	The study takes a cross-sectional mixed methods approach, utilising an adapted version of an
35	International Decision Support Initiative questionnaire with both semi-structured and open-ended
36	questions. We interviewed thirty key informants from different stakeholder institutions in
37	Uganda that have decision making roles in the health sector.
38	
39	Results
40	All participants perceived HTA as an important tool for decision making. Allocative efficiency
41	was regarded as the most important use of HTA receiving the highest average score (8.8 out of
42	10), followed by quality of healthcare (7.8/10), transparency (7.6/10), budget control (7.5/10)
43	and equity $(6.5/10)$. There was concern that some of the uses of HTA may not be achieved in
44	reality if there was political interference during the HTA process. The technology areas that
45	interviewees highlighted as needing HTA type evaluations urgently were identified as medicines
46	(60.0% of the participants), diagnostics (53.3%), vaccines (40.0%), and public health programs

47	(26.7%). The study participants identified development partners as the most likely potential users
48	of HTA (66.7% of participants), followed by Ministry of Health (43.3%).
49	
50	Conclusion
51	Interviewed stakeholders in Uganda viewed the role of HTA positively, suggesting that there
52	exists a promising environment for the establishment and operationalisation of HTA as a tool for
53	decision making within the health sector. However, sustainable development and application of
54	HTA in Uganda will require adequate capacity both to undertake HTAs and to support their use
55	and uptake.
56	
57	
58	Key words: Health Technology Assessment (HTA), Perception and experiences, Uganda
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

70

71 Introduction

Priority setting is a key aspect of attaining universal health coverage (UHC)¹. UHC is commonly interpreted as people and communities receiving the health services they need without experiencing financial hardship no matter who they are or where they are². Many low- and middle-income countries (LMICs) are aiming to achieve UHC by 2030, introducing reforms, for example, to remove financial barriers to care and eradicate the financial burden to the patients and their households. Some of the countries enacting UHC-relevant reforms include among others, Vietnam³, China⁴, Ghana⁵, Uganda⁶ and Zambia⁷.

79

80 Many UHC reforms in LMICs are focused at increasing the available resources for the health system while reducing out of pocket expenditure on health⁸. This leaves out the element of how 81 82 the resources are spent, the purchasing function of the health financing building block of the 83 health system. This includes the process by which funding priorities are made (priority setting 84 for health). As countries grapple with increasing resource constraints with many emphasizing the 85 need to maximise value for money, current institutional structures are often inadequate to support the efficient allocation and use of available resources⁹. Most decisions (including priority setting 86 decisions) are made in ad hoc and implicit manner^{10,11}. However, some countries have made 87 88 progress in this space through incorporating evidence-informed decision-making (EIDM) 89 approaches in health policies as a means to effectively and efficiently respond to the health needs 90 of served populations. The World Health Organisation defines EIDM as a systematic and 91 transparent approach that applies structured and replicable methods to identify, appraise and make use of evidence across decision-making processes, including for implementation 12 . 92

93

94 The WHO asserts that priority setting decisions should be informed by the best available 95 evidence from research, as well as other factors such as context, public opinion, equity, 96 feasibility of implementation, affordability, sustainability, and acceptability to stakeholders¹². 97 Countries in the global south have increasingly introduced EIDM mechanisms such as health 98 technology assessment (HTA); or at least expressed a desire to do so^{13–15}.

99

100 HTA has been defined as a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle¹⁶. The purpose is to inform 101 102 decision-making in order to promote an equitable, efficient, and high-quality health system¹⁷. 103 HTA has been highlighted by the WHO as one of the tools that can propel countries towards 104 UHC if implemented. Examples of countries recently introducing HTA in decision making include Ghana^{15,18}, India¹⁹, Kenya²⁰, Indonesia²¹, and the Philippines²². Uganda is committed to 105 106 the achievement of UHC by 2030 through strengthening the health system and its support mechanisms with a specific focus on primary health care²³. The Ministry of Health (MoH) sees 107 108 HTA as one of the tools that can enable the country make further progress towards UHC.

109

110 The International Decision Support Initiative (iDSI), a global network of priority setting support 111 institutions and experts, received a request from the Ugandan MoH to facilitate the 112 institutionalisation of HTA in the country²⁴. Institutionalisation of HTA involves the 113 establishment and operationalisation of HTA structures and processes that enable the sustainable 114 production and utilisation of HTA evidence.

As an initial step, and to inform any strategy to implement HTA in Uganda, a situational (or landscape) analysis that examines existing priority setting approaches and the potential capacity to use evidence in decision making was considered necessary. The present study, a component of a wider situational analysis, aimed to understand the perceptions of stakeholders in Uganda towards HTA to inform HTA implementation in the country.

121

122 Methods

123 Study Design

124 This is a cross-sectional mixed methods study utilising a questionnaire with both semi-structured125 and open-ended questions.

126

127 Context

128 The study was carried out in Uganda, a country located in East Africa. Uganda is a low income country with a gross domestic product per capita of USD 883.9²⁵ and a population of 47 million 129 as of 2021²⁶. The Ugandan health system is decentralized from MoH to the districts but with the 130 131 financing still largely controlled by the central government, there is little allocative authority 132 available to the districts. The MoH is responsible for policy formulation, planning, quality 133 assurance, epidemic response, international relations, resource mobilization and monitoring and 134 evaluation. Most decision making takes place at the Ministry level. The budgetary allocations to 135 the health sector have been increasing over time from 560 billion Uganda Shillings (UGX) in the financial year (FY) 2010/11 to 911 billion UGX in 2018/19²⁷. However, the MoH budget as a 136 137 share of the total government budget has been showing a downward trend even before COVID-19 pandemic. The budget declined from 11.2% in 2004/5 to 5.1% in 2020/21²⁸. Out-of-pocket 138

expenditure on health as a proportion of the national current health expenditure remains high at $40\%^{29,30}$.

141

Uganda has a total of 6,937 health facilities and clinics at different levels in 128 districts³¹. The biggest share of all health facilities is government owned at 45.16% (3,133); another 14.44% (1,002) are Private and Not-For-Profit (PNFP), 40.29% (2,795) are Private for Profit (PFP) and 0.10% (7) community-owned facilities. Uganda has made improvements in healthcare coverage in recent years. The Government of Uganda planned to have at least 85% of the population living within five kilometres of a health facility by 2020 from 75% as of 2015³². This target however has not yet been achieved³³.

149

150 Data collection tool

The iDSI HTA situational analysis survey questionnaire³⁴ was used to collect data from key 151 152 informants. The questionnaire has previously been used in a survey of Sub-Saharan African countries and also in a more in depth study focused on Nigeria³⁵. The questionnaire was adapted 153 154 to the Uganda setting and used to collect the primary data. The adaptation of the tool was done 155 during a one-day virtual workshop organised by the research team consisting of members from 156 Makerere University School of Public Health (MakSPH), MoH and iDSI (co-authors on this 157 study). The questionnaire is divided into two parts: a closed ended (quantitative) series of 158 questions focused on the uses and importance of HTA; and an open-ended questionnaire section 159 that seeks information on the need, demand and supply of HTA. The quantitative sections score 160 the importance of HTA in a number of dimensions: achieving allocative efficiency; quality of 161 care; transparency in decision making; budget control; and equity. The scores ranged from 0 to

162 10, where 0 is 'not important' and 10 is 'very important'. The key informants were expected to 163 answer both the quantitative and qualitative sections of the questionnaire. The questionnaire was 164 pretested among 5 non-key informants at the MoH to ensure that the questions were clear and 165 uniformly understood by the people answering them.

166

167 Study participants

168 Participants were people in decision making positions within their organisations or institutions. 169 They were purposively selected to represent a variety of stakeholder institutions involved in 170 policy making in the health sector which are likely to utilise and supply HTA evidence. The 171 selection of the key informants was based on expertise, experience, and role in the decision-172 making and resource-allocation/prioritization processes in the health sector at both regional and 173 national level. The key informants were identified through a rapid literature review, and 174 consultations with the MoH. The key informants included: representatives of the professional 175 councils, for example the Uganda Medical and Dental Practitioners Council; District health 176 officers; development partners; government institutions such as the National Drug Authority; 177 investigators at academic and research institutions; and non-governmental organisations. The 178 interviews took place between January and March 2022.

179

180 Administration of the questionnaire

Appointments were made with the participants prior to the interview day. The interviews were conducted either in person or virtually via Zoom taking into account the key informant's preference and the existing COVID 19 guidelines in the country at that time. The questionnaire was interviewer-administered. All interviews were recorded. In addition, the interviewer took

185 notes during the interview which were handed over to the principal investigator after the 186 interview for referencing during analysis.

187

188 Data processing and analysis

189

190 The recorded interviews were transcribed. The quantitative data were cleaned and descriptively 191 analysed using Microsoft Excel. The data was summarised narratively in addition to using tables 192 and graphs.

193

194 The qualitative data was analysed using the inductive thematic analysis method³⁶ taking the 195 constructionist thematic approach. Validation of results was done through a meeting with the 196 stakeholders.

197

198 Ethical considerations

199 This study was reviewed and approved by the MakSPH Higher Degrees Research and Ethics 200 Committee (HDREC), approval number SPH-2021-151. The study was registered with the 201 Uganda National Council of Science and Technology. Ethical approval was also sought from and 202 granted by the London School of Hygiene and Tropical Medicine Ethics Committee (LSHTM 203 Ethics Ref: 26615). During data collection, ethical principles were upheld in the study including: 204 1) maintaining the level of confidentiality; 2) Informant's participation was voluntary 3) 205 obtaining written informed consent; and 4) no study materials contained names or other explicit 206 identifiers of participants.

208 Results

A total of thirty stakeholders from governmental, non-governmental and private sector institutions were interviewed to understand their perceptions towards the use of HTA in decision making. Supplementary material 1 shows the list of institutions from which the key informants where selected.

213

Proportionately, the key informants included in this study reflected a balanced representation of the supply and demand side of HTA in the country. The supply side of HTA was mostly represented by academic institutions (n=5) while the majority of key informants on the demand side were government ministries (n=8).

218

219

220 **Perceived use of HTA**

The stakeholders perceived achieving allocative efficiency, quality of care, transparency in decision making, budget control and equity as key uses of HTA. Each of these aspects had average scores greater than six out of 10 (where 10 indicates the use is "very important"). Allocative efficiency was scored as the most important use of HTA gaining an average score of 8.8. Below is figure 1, a graph showing the average scores awarded to each of the HTA benefits.

226

227 Figure 1: Perceived importance of HTA among stakeholders







Value for money and optimal use of resources were common reasons provided for scoring allocative efficiency highly. Health technology assessments were viewed by many as a way of getting the best value from the available resources enhancing the efficiency of the health system.

"Health Centre IV, we give resources in the same way that we give... other lower-level facilities, and yet you know very well that almost 30% of these health centres are not carrying out operations but they are getting money like the health centre IVs which are having like 60 or 50 operations per month. So, there you are not allocating your resources efficiently. There is no allocative efficiency in that aspect. So, it means that you need to have that information and you need to develop that criterion, the whole of that formula then you can be able to say that you can efficiently allocate, we must be conscious of what we are doing...." key informant (K3)

240

Others emphasized the need for transparency in decision making to ensure that the resource allocation is aligned with the main problems from the communities' perspective. A key reason for adopting HTA was that it would help improve the quality of health care.

"Improving the quality of healthcare, …… requires having in place tools that can help you to continuously assess and identify the gap on a regular basis. So, if you go manual, you cannot get all the information and analyse it in time and triangulate and give you a good assessment of the different perspectives of quality.... HTA can assist in ensuring provision of quality services" Key informant (K9)

249 "why would I give it [improving quality of healthcare] a higher score... because interventions
250 implemented based on evidence are less prone to embezzlement. ..., resources are put to their

251 *best use*." Key informant (K23).

252

Despite a high score on the *need* for HTA, many respondents acknowledged that there could be a less-than-optimal use of HTA in actual decision making due to political pressures and other considerations. For example, limited resources and capacity may not support the actual use of evidence in practice.

"I will give it about 8 (allocative efficiency), because as much as you can have the assessment
[HTA] done,...when it comes to decision making, there are other factors that also influence
things like political decisions, interests and all that. It is good, but you cannot rely on it 100%".
Key informant (K9).

261

262 Areas that require HTA urgently

Each respondent was asked to identify three technology (or intervention) areas that they thought urgently required HTA. A number of areas were identified including medicines, medical devices and diagnostics, public health programs, vaccines, screening programs, and service delivery incentives (Figure 2).

267



268 Figure 2: Areas that require the use of HTA urgently

269

270

The assessment of medicines was identified as the area HTA was most urgently needed (18 respondents [60.0%]), followed by medical devices and diagnostics (16 respondents [53.3%]), and vaccines (12 respondents [40.0%]) in third place (figure 2).

274

Most respondents highlighted that these technology areas are expensive relative to the limited available resources. Other issues noted by respondents included the use of expensive first line drugs by Ugandan health providers, especially in the private sector, despite the availability of more affordable alternatives.

".... these are things (Medicines, vaccines, and medical devices) which are common in a health system service delivery and because they are there, we interface with them whether you are a patient or not. [...] The diagnostic devices [....], people are taken advantage of with these devices so I think to help the user, these need to go through HTA process and government or the country makes a statement on the various diagnostics; then the private sector is unlikely to take advantage of the population" Key informant (K10)

286

287 **Potential users of HTA outputs**

288 Respondents were asked for the likely users of HTA outputs. Figure 3 shows the frequency of

- 289 perceived likely users of HTA outputs in Uganda.
- 290



291 Figure 3: Likely users of HTA evidence

293 Development partners were perceived to be most likely users of HTA output (20 of 30 294 respondents) followed by the MoH and its subsidiaries (13 of 30). Only five respondents 295 perceived pharmaceutical and private firms as potential users of HTA outputs, while civil society

- 296 organisations (CSO), community and research institutions were seen as potential users of HTA
- 297 output by less than five respondents.
- 298

299 Perceived level and type of HTA evidence needed by major stakeholders

300 Respondents scored the extent to which the different type of HTA outputs are needed by the

301 major categories of stakeholders (figure 4).

302

303 Figure 4: Perceived need for the different types of HTA outputs by stakeholders



305

All the different potential HTA outputs (relating to safety, efficacy, effectiveness, economic and
social/ethical concerns) are seen to be needed and helpful to all categories of stakeholders (table
1). All the outputs were scored at least five out of ten for each category of stakeholders.
'Efficacy' was scored at 5/10 for the CSO and community stakeholders.

310

311 *Table 1:* Level of interest in different types of HTA outputs

Organization	Safety	Efficacy	Effectiveness	Economics	Social/Ethical
--------------	--------	----------	---------------	-----------	----------------

					concerns
Development Partners	8.00	7.50	8.14	9.37	9.25
MOH and its Agencies (NMS,	9.00	8.85	9.53	9.06	8.41
UNITAG, NDA)					
Other Government Agencies	8.75	6.00	8.83	9.57	8.71
(MoFPED, NPA, KCCA, UBOS					
Pharmaceutical and private firms	8.67	9.33	9.33	8.67	7.00
(JMS)					
CSO and Community	10.00	5.00	8.00	10.00	10.00
Research and Academic Institutions	9.25	9.50	9.00	6.67	8.00

312 Source: Averaged from respondent scores

313

314 The CSO category of stakeholders was perceived to be the most interested in safety related 315 outputs of HTA (10.00/10) followed by research and academic institutions (9.25/10), and the 316 MoH and its subsidiaries (9.00/10). Research and academic institutions were identified as the 317 most interested in efficacy aspects (9.50/10) followed by pharmaceutical and private firms 318 (9.33/10). The MoH and its subsidiaries was identified as the stakeholder most interested in 319 effectiveness outputs of HTA (9.53/10) followed by pharmaceutical and private firms (9.33/10). 320 The CSO were perceived to be the most interested in economic-related HTA outputs (10 out of 321 10), followed by development partners (9.37/10). The ranking of the interest of the stakeholders 322 in social/ethical concerns was similar to the interest in economic evidence. 323

324

325 Discussion

This study shows that HTA stakeholders (decision makers) on both the supply and demand sides of HTA perceive HTA as an important tool for decision making within the health sector in Uganda. According to this study, seeking allocative efficiency is the most important goal when implementing HTA, and medicines were identified as the main technology area where the application of HTA type analyses were long overdue. Notably, development partners were perceived to be the most likely users of HTA outputs.

332

333 Resource allocation was perceived as the most prominent use of HTA according to the stakeholders in Uganda. This is consistent with findings in India³⁴ and Nigeria³⁵ where similar 334 surveys have been done. HTA has been taken to be synonymous with cost effectiveness³⁷ and 335 336 limited to the end result of resource allocation or some assessment of value-for-money. 337 However, HTA arguably offers further benefits in terms of transparency, support for equity 338 considerations and stakeholder inclusiveness, as part of an overarching priority setting decision process^{38–40}. HTA is not a narrow technical exercise; it provides a framework to accommodate 339 340 multiple considerations/criteria including potentially 'political factors' within a multi-stakeholder 341 engagement process. A good HTA process follows pre-agreed rules and offers transparency with 342 respect to how any evidence is considered in decision making. These factors enhance the 343 credibility and social legitimacy of often difficult priority setting choices⁴¹.

344

345 Development partners were identified as the most likely users of HTA in Uganda in this study 346 which differs from the findings of similar studies in other countries. In Nigeria and India, it was 347 found that that federal and state governments were seen as the dominant users of HTA 348 outputs^{34,35}. This difference could reflect variation in development partner influence in resource

349 allocation decisions in these settings. In both Nigeria and India, the state governments have 350 extensive authority to make such decisions, while in Uganda, most of the health care resources 351 have been ear-marked already, and to a significant extent these ear-marked resources are 352 supported by funding from development partners. Indeed, development partners fund approximately 40% of the Ugandan health budget³⁰. The findings from Uganda may also reflect 353 354 the stakeholders' association of HTA with primarily the allocation of resources for specific 355 technologies, with less consideration of other uses such as informing the development of clinical 356 guidelines. Further sensitisation of Ugandan stakeholders on the nature and use of HTA may 357 change perceptions around key beneficiaries of implementation.

358

359 It is perhaps concerning that the MoH is not seen as the most likely user of HTA evidence 360 despite the fact that it is the institution responsible for policy formulation and implementation 361 within the health sector. This may in part be a result of the relatively low engagement of 362 stakeholders by the MoH on the topic of HTA. This suggests that there could be value in the 363 MoH (with the support of international partners as needed) in actively engaging with relevant 364 stakeholders, and advocate for a potential legal framework to guide the operationalisation and 365 institutionalisation of HTA in the country. Building HTA within a legal framework that requires 366 it use for coverage decisions could be valuable in aiding implementation, especially in environments where there is a national social insurer⁴². For example, the Philippines put in place 367 368 an HTA organisational structure informed by a statutory law that established the Health 369 Technology Assessment Council (HTAC), an independent advisory institution which gives 370 guidance to the Philippines Government Department of Health and the Philippine Health

Insurance Corporation (PhilHealth) on which health interventions/technologies are to be funded
 by the government²².

373

374 Uganda, through the MoH, is in fact pursuing a legal framework detailing the processes through 375 which priority setting decisions are made and operationalised. However significant progress can 376 still be made in the absence of a detailed legal underpinning for HTA. For example, Thailand has 377 developed robust HTA systems without a specific legal framework and has created a semiautonomous unit to serve as an agency to inform decisions using HTA⁴³. Rwanda, while not 378 379 having a dedicated HTA unit, is currently applying HTA approaches to update the health benefits package of the community-based health insurance scheme⁴⁴. Uganda could therefore explore 380 381 setting up preliminary, exploratory structures to support HTA development, such as an HTA unit 382 perhaps within the MoH, in advance of a formal legal framework. This would allow for testing 383 potential options and processes.

384

The relative absence of HTA-like approaches in decision making in Uganda was seen by the stakeholders interviewed as disadvantaging the patients and people in Uganda in general. The cost of medicines is not regulated and patients are seen as being taken advantage of. This potentially exposes patients and their households to catastrophic health expenditures. It is for these reasons that respondents see HTA as a tool to support development of the national drug formulary, standardize reimbursement of expenses especially for provider payment systems and also improve health outcomes of the final users.

The establishment of HTA structures is likely to stimulate and increase HTA capacity in the country. Currently, there is a limited HTA relevant literature that focuses on the Ugandan context, and the majority of those studies are authored by researchers based in other countries, a situation similar to LMICs more generally⁴⁵. The existence of HTA structures will further enhance the value of the awaited Master of Health Economics program by Makerere University which will train health economists in-country that could then be absorbed into those HTA structures.

400

401 Building in-country HTA structures will however still need the support of international 402 organisations and donors for the foreseeable future. There are a number of development partners 403 that are engaging in HTA relevant activities within the country including the Medical Research 404 Council/Uganda Virus Research Institute and LSHTM Uganda Research Unit, the University of 405 York under Thanzi la Onse, the Professional Society for Health Economics and Outcomes 406 Research (ISPOR), Results for Development (R4D), ThinkWell, Strategic Purchasing Africa 407 Resource Centre (SPARC), Norwegian Institute of Public Health (NiPH), and KEMRI-408 Wellcome Trust. Although important for supporting domestic HTA institutionalisation, in most 409 cases development partners tend to carry out activities in isolation leading to duplication and 410 unnecessary competition if unregulated within a given country. There is therefore a need for the 411 MoH to encourage collaboration and coordination among these stakeholders to avoid duplication 412 of HTA related activities and optimize impact.

413

414 Limitations

415 The study included respondents that were in decision making positions within their 416 organizations. The findings may not reflect mid-level and low-level managers within those 417 institutions. The stakeholders selected were mostly from the central region of Uganda which is 418 generally urban and houses the headquarters of MoH and most key institutions. Therefore, the 419 findings of this study may not reflect the perceptions of decision makers that are based in rural 420 parts of the country. The level of understanding of HTA varied across stakeholders, where those 421 with a background in health economics having more knowledge on the subject matter than 422 others. This may have introduced some level of bias in the findings.

423

424 Conclusion

425 Key stakeholders in Uganda took a positive view of the role of HTA suggesting a promising 426 environment for the establishment and operationalisation of HTA as a tool for decision making 427 within the health sector. Sustainable development and application of HTA in Uganda will require 428 adequate capacity both to undertake HTAs and to support their use and uptake. There is perhaps 429 a need for a more comprehensive understanding of current HTA capacity in Uganda, which takes 430 into account the different needs and requirements of the stakeholders involved, the existing 431 priority setting processes and notes the importance of strengthening both technical and non-432 technical (e.g. administrative) aspects necessary for the conduct of HTA. Supported by 433 development partners and under the leadership of Ugandan authorities, it may be necessary to 434 undertake a detailed capacity assessment exercise in order to better understand existing strengths 435 and where current expertise is located. This would inform a national strategy for capacity 436 building in HTA going forward.

438 **Declaration**

439

440 Ethics approval and consent to participate

- 441 This study was reviewed and approved by the MakSPH Higher Degrees Research and Ethics
- 442 Committee (HDREC), approval number SPH-2021-151 and the London School of Hygiene and
- 443 Tropical Medicine Ethics Committee (LSHTM Ethics Ref: 26615).

444

- 445 **Consent for publication**
- 446 Not applicable

447

448 Availability of data and materials

449 The data analysed during the current study is available from the corresponding author upon

450 reasonable request.

451

452 **Competing interests**

453 The authors declare that they have no competing interests

454

455 Funding

- 456 This study was supported by the International Decision Support Initiative, which is funded by the
- 457 Bill and Melinda Gates Foundation (OPP1202541).

458

459 **Role of funder**

- 460 The funder of the study had no role in study design, data collection, data analysis, data
- 461 interpretation, or writing of the report. Funders supported researcher time and other resources
- 462 (such as computer equipment) needed for completion of the study.
- 463

464 **Authors contributions**

- 465 Conceptualisation: MG, JK, FR, FS, CM
- 466 Developing protocol: JK, CM, RS, AS, EE, SB, TA, TM, AV, FR
- 467 Data collection: RS, BN
- 468 Validation: JK, FR, EE
- 469 Data curation and analysis: JK, RS, BN
- 470 Funding acquisition: FR, AV
- 471 Methodology: JK, CM, FR, AV
- 472 Project administration: JK, MG
- 473 Supervision: FR, FS
- 474 Writing original draft: JK, CM, RS
- 475 writing review & editing: JK, CM, RS, BN, AS, EE, SB, TA, TM, MG, AV, FR, FS
- 476
- 477 Acknowledgements
- 478 None
- 479
- 480 **References**
- 481 1. WHO Consultative Group on Equity and Universal Health Coverage. *Making Fair*
- 482 *Choices on the Path to Universal Health Coverage.*; 2014. Accessed September 2, 2022.

- 483 http://www.ncbi.nlm.nih.gov/pubmed/25666865
- 484 2. World Health Organisation. Universal health coverage (UHC). Published April 1, 2021.
- 485 Accessed June 12, 2022. https://www.who.int/news-room/fact-sheets/detail/universal-
- 486 health-coverage-(uhc)
- 487 3. Tran Van Tien by, Thi Phuong H, Mathauer I, Thi Kim Phuong N. A Health Financing
- 488 Review of Vietnam with a Focus on Social Health Insurance: Bottlenecks in Institutional
- 489 Design and Organizational Practice of Health Financing and Options to Accelerate
- 490 *Progress towards Universal Coverage.*; 2011.
- 491 4. Zhang J, Zeng H, Yu T, Zhang R. China's universal healthcare reform: the first phase
- 492 [2009–2011] of the ambitious plan. J Hosp Manag Heal Policy. 2018;2:22-22.
- 493 doi:10.21037/JHMHP.2018.04.09
- 494 5. Fusheini A. Healthcare Financing Reforms: Ghana's National Health Insurance. *Heal*
- 495 *Reforms Across World*. Published online March 2020:25-54.
- 496 doi:10.1142/9789811208928_0002
- 497 6. Cashin C, Dossou J-P. Can National Health Insurance Pave the Way to Universal Health
- 498 Coverage in Sub-Saharan Africa? *https://doi.org/101080/2328860420212006122*.
- 499 2021;7(1). doi:10.1080/23288604.2021.2006122
- 500 7. Masiye F, Chansa C. *Health Financing in Zambia*.; 2019.
- 501 8. Jalali FS, Bikineh P, Delavari S. Strategies for reducing out of pocket payments in the
- 502 health system: a scoping review. *Cost Eff Resour Alloc*. 2021;19(1):1-22.
- 503 doi:10.1186/S12962-021-00301-8/TABLES/5
- 504 9. Glassman A, Chalkidou K, Giedion U, et al. Priority-Setting Institutions in Health:
- 505 Recommendations from a Center for Global Development Working Group. *Glob Heart*.

506 2012;7(1):13-34. doi:10.1016/J.GHEART.2012.01.007

- 507 10. Baltussen R, Niessen L. Priority setting of health interventions: The need for multi-criteria
- 508 decision analysis. *Cost Eff Resour Alloc*. 2006;4(1):1-9. doi:10.1186/1478-7547-4-
- 509 14/FIGURES/2
- 510 11. Chalkidou K, Levine R, Dillon A. Helping poorer countries make locally informed health
- 511 decisions. *BMJ*. 2010;341(7767):284-286. doi:10.1136/BMJ.C3651
- 512 12. World Health Organsiation. Evidence, Policy, Impact: WHO Guide for Evidence-Informed
- 513 *Decision-Making*.; 2022. Accessed December 14, 2022.
- 514 https://www.who.int/publications/i/item/9789240039872
- 515 13. Downey LE, Mehndiratta A, Grover A, et al. Institutionalising health technology
- 516 assessment: establishing the Medical Technology Assessment Board in India. *BMJ Glob*

517 *Heal*. 2017;2(2):e000259. doi:10.1136/BMJGH-2016-000259

- 518 14. MacQuilkan K, Baker P, Downey L, et al. Strengthening health technology assessment
- 519 systems in the global south: a comparative analysis of the HTA journeys of China, India
- and South Africa. *Glob Health Action*. 2018;11(1).
- 521 doi:10.1080/16549716.2018.1527556/SUPPL_FILE/ZGHA_A_1527556_SM6628.ZIP
- 522 15. Groom G, Groom, Genevive. Final Report: iDSI learning review: Ghana. F1000Research

523 2019 8840. 2019;8:840. doi:10.7490/F1000RESEARCH.1116868.1

- 524 16. World Health Organisation. International HTA networks. Accessed April 15, 2021.
- 525 https://www.who.int/health-technology-assessment/networks/en/
- 526 17. O'Rourke B, Oortwijn W, Schuller T. The new definition of health technology
- 527 assessment: A milestone in international collaboration. *Int J Technol Assess Health Care*.
- 528 2020;36(3):187-190. doi:10.1017/S0266462320000215

- 529 18. Bidonde J, Meneses-Echavez JF, Asare B, et al. Developing a tool to assess the skills to
- 530 perform a health technology assessment. *BMC Med Res Methodol*. 2022;22(1):78.
- 531 doi:10.1186/S12874-022-01562-4/FIGURES/3
- 532 19. Ministry of Health and Family Welfare Department of Health Research India. Health
- 533 Technology Assessment in India (HTAIn). Published 2018. Accessed April 30, 2023.
- 534 https://htain.icmr.org.in/
- 535 20. Ministry of Health. Government launches health technology assessment to inform policy
- 536 decision making Nairobi, Kenya. Published March 2018. Accessed April 30, 2023.
- 537 https://www.health.go.ke/government-launches-health-technology-assessment-to-inform-
- 538 policy-decision-making-nairobi-kenya-18-march-2018/
- 539 21. Sharma M, Teerawattananon Y, Luz A, Li R, Rattanavipapong W, Dabak S.
- 540 Institutionalizing Evidence-Informed Priority Setting for Universal Health Coverage:
- 541 Lessons From Indonesia. *Inq (United States)*. 2020;57. doi:10.1177/0046958020924920
- 542 22. Republic of Philippines Department of Health. Health Technology Assessment Council
- 543 (HTAC) . Accessed April 30, 2023. https://hta.doh.gov.ph/health-technology-assessment544 council-htac/
- 545 23. Ministry of Health. Ministry of Health Strategic Plan 2020/21 2024/25 Ministry of
- 546 Health | Government of Uganda. Published 2020. Accessed September 2, 2022.
- 547 https://www.health.go.ug/cause/ministry-of-health-strategic-plan-2020-21-2024-25/
- 548 24. International Decision Support Initiative (iDSI). iDSI. Accessed September 6, 2022.
- 549 https://www.idsihealth.org/
- 550 25. The World Bank. GDP per capita (current US\$) Uganda. Published 2022. Accessed
- 551 April 30, 2023. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=UG

- 552 26. The World Bank. Uganda . Published 2022. Accessed December 14, 2022.
- 553 https://data.worldbank.org/country/UG
- 554 27. Ministry of Finance Planning and Economic Development. Good Governance; a
- 555 *Prerequisite to Harness the Demographic Dividend for Sustainable Development. State of*
- 556 Uganda Population Report 2018.; 2018.
- 557 28. UNICEF. The National Budget Framework Paper 2020/21 Budget Brief.
- 558 29. Kadowa I. A Case Study of the Uganda National Minimum Healthcare Package the Role
- 559 of Essential Health Benefits in the Delivery of Integrated Services: Learning from
- 560 *Practice in East and Southern Africa.*; 2017.
- 561 30. Ministry of Health Uganda. National Health Accounts 2016-2019.; 2022.
- 562 31. Ministry of Health of the Republic of Uganda. *National Health Facility Master List.*;
 563 2018.
- 564 32. Ministry of Health Uganda. Health Sector Development Plan 2015/16 2019/20.
- 565 Published 2015. Accessed January 8, 2022. https://www.health.go.ug/cause/health-sector-
- 566 development-plan-2015-16-2019-20/
- 33. World Health Organisation African Region. Uganda on the right path to achieving
 Universal Health Coverage. Accessed April 30, 2023.
- 569 https://www.afro.who.int/news/uganda-right-path-achieving-universal-health-coverage
- 570 34. Dabak SV, Pilasant S, Mehndiratta A, et al. Budgeting for a billion: Applying health
- 571 technology assessment (HTA) for universal health coverage in India. *Heal Res Policy*
- 572 *Syst.* 2018;16(1):1-7. doi:10.1186/S12961-018-0378-X/TABLES/2
- 573 35. Uzochukwu BSC, Okeke C, O'Brien N, Ruiz F, Sombie I, Hollingworth S. Health
- 574 technology assessment and priority setting for universal health coverage: A qualitative

- 575 study of stakeholders' capacity, needs, policy areas of demand and perspectives in
- 576 Nigeria. *Global Health*. 2020;16(1):1-11. doi:10.1186/S12992-020-00583-2/TABLES/6
- 577 36. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*.
- 578 2006;3(2):77-101. Accessed January 26, 2023. https://uwe-
- 579 repository.worktribe.com/preview/1043068/thematic_analysis_revised_-_final.pdf
- 580 37. Teerawattananon Y, Painter C, Dabak S, et al. Avoiding health technology assessment: a
- 581 global survey of reasons for not using health technology assessment in decision making.
- 582 *Cost Eff Resour Alloc*. 2021;19(1):1-8. doi:10.1186/S12962-021-00308-1/FIGURES/3
- 583 38. Pan American Health Organisation and World Health Organisation. Health Technology
- 584 Assessment (HTA). Published 2013. Accessed April 30, 2023.
- 585 https://www3.paho.org/hq/index.php?option=com_content&view=article&id=9229:2013-
- 586 tecnologias-sanitarias&Itemid=41687&lang=en#gsc.tab=0
- 587 39. Gagnon MP, Desmartis M, Lepage-Savary D, et al. Introducing patients' and the public's
- 588 perspectives to health technology assessment: A systematic review of international
- 589 experiences. *Int J Technol Assess Health Care*. 2011;27(1):31-42.
- 590 doi:10.1017/S0266462310001315
- 591 40. Gagnon MP, Tantchou Dipankui M, Poder TG, Payne-Gagnon J, Mbemba G, Beretta V.
- 592 Patient and public involvement in health technology assessment: update of a systematic
- 593 review of international experiences. *Int J Technol Assess Health Care*. 2021;37(1):e36.
- 594 doi:10.1017/S0266462321000064
- 595 41. Rocchi A, Chabot I, Glennie J. Evolution of health technology assessment: best practices
- 596 of the pan-Canadian Oncology Drug Review. *Clin Outcomes Res.* 2015;7:287-298.
- 597 doi:10.2147/CEOR.S82549

- 598 42. Bertram M, Dhaene G, Edejer TT-T. Institutionalizing Health Technology Assessment
- 599 *Mechanisms: A How to Guide.*; 2021. Accessed May 13, 2023.
- 600 https://apps.who.int/iris/handle/10665/340722
- 601 43. Sharma M, Teerawattananon Y, Dabak SV, et al. A landscape analysis of health
- 602 technology assessment capacity in the Association of South-East Asian Nations region.
- 603 *Heal Res Policy Syst.* 2021;19(1):1-13. doi:10.1186/S12961-020-00647-0/FIGURES/3
- 604 44. Government of Rwanda. Rwanda Ministerial Instructions determining the methodology to
- define the community-based health insurance benefit package . Published August 31,
- 606 2021. Accessed April 27, 2022. https://gazettes.africa/archive/rw/2021/rw-government-
- 607 gazette-dated-2021-08-31-no-special.pdf
- 608 45. Hollingworth S, Fenny AP, Yu SY, Ruiz F, Chalkidou K. Health technology assessment
- 609 in sub-Saharan Africa: a descriptive analysis and narrative synthesis. *Cost Eff Resour*

610 *Alloc*. 2021;19(1):1-13. doi:10.1186/S12962-021-00293-5/TABLES/2

- 611
- 612